Neuropharmacology 2019

About Conference

Currently we are bringing forth "27^th Global Experts Meeting on Neuropharmacology” (Neuropharmacology 2019) scheduled to be held during November 18-19, 2019 at Rome, Italy. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Pharmacology and Neuropharmacology.

Why to attend???

With members from around the world focused on learning about neuropharmacology and its advances; this is your best opportunity to reach the largest assemblage of participants from the Neuropharmacology community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Neuropharmacology are hallmarks of this conference.

Scientific Sessions

Track 01: Neuroimmunology and Neuroinflammation

It deals with a branch of immunology concerned with the interactions between immunological and nervous system functions also associated autoimmune diseases. Encephalitis is acute inflammation of the brain resulting from a viral infection or an autoimmune disease. Transverse myelitis is a pathogenetically heterogeneous inflammatory disorder in which spinal cord is affected. Huntington disease is a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability.

Related Conferences: Neuropharmacology Conferences | Toxicology Congress | Neurology Conferences | Pharmacology Conferences | Neurochemistry Conferences | Neuroscience Conferences | Euro Neuropharmacology Conferences | Parkinsons Conferences

Track 02: Neural Stem Cell

Neural stem cells (NSCs) offer a unique and powerful tool for basic research and regenerative medicine. To date the need to accomplish this has just been met to some degree for neurons got from embryonic undeveloped cells or iPS cells, and still, after all that the information is not of a quality to justify clinical trials. The issue is that, while the cells that can be made in the lab resemble the ones required, they frequently do not have certain fundamental attributes.

Track 03: Neuroethics

It includes the social, legal and ethical consequences of advances in neuroscience. It is the amalgamation of neuroscience with ethical thoughts. The ethics of neurocognitive includes brain interventions and imagining, neurological treatments and consciousness disorders.

Track 04: Clinical Neuropharmacology

It is the science that studies the features, properties, responses and uses of drugs mainly their therapeutic effect in humans along with toxicology, pharmacodynamics and pharmacokinetics. It also includes drug abuse, pain and hypothalamic releasing factors.

Track 05: Psychopharmacology

Psychopharmacology is the learning of the effects of medication on the psyche (psychology), observing changed behaviors and how molecular events are manifest in a measurable behavioral form. Neurogenesis and repair deal with other aspects on the indications for medications prescribed to address psychiatric and behavioral problems. The treatments may cause side effects such as induction of the metabolic syndrome, type II diabetes related to the medications prescribed for management of psychiatric and behavioural disorders and disturbances. Schizophrenia is such a disorder which affects the thinking and acting ability of a person caused by viral infection, genetically or by immune disorder.

Track 06: Neurochemical Transmission

Neurochemistry is the specific study of neurochemicals, including neurotransmitters and other molecules that include psychopharmaceuticals, neuropeptides, or gastrotransmitters that influence the function of neurons. It also deals how these neurochemicals influence the network of neural operation. The studies include micro-macro connection between the analysis of organic compounds active in the nervous system and neural processes such as cortical plasticity, neurogenesis and neural differentiation, synapses, autism and intellectual disability, interneuronal coordination, interaction of drugs and its effect on summation and cotransmission process and advances in astrocyte-neuron interactions in health. Astrocyte dysfunction results into neurodegenerative diseases, stroke, epilepsy, migraine and neuroinflammatory diseases.

Track 07: Behavioral and Addiction Neuropharmacology

It is the study of drug dependence and how drug addiction affects the human mind, anxiety and autism, Measuring neural activity in Drug abuse, Alcoholism- tolerance to and physical dependence, and properties are mediated through its effects on dopamine neurons in the mesolimbic reward pathway, which connects the ventral tegmental area to the nucleus accumbens, Post-traumatic stress disorder and borderline personality disorder, clinical depression and enhanced treatments.

Track 08: Neurotechnology

It is the measurement and analysis of chemical and electrical signals of nervous system. It includes neurocircuitary analysis, novel trans-synaptic tracing approaches, advancements of optical techniques, neuromodulation and transcranial magnetic stimulation. Neurotechnology plays a crucial role in diagnostics and identification of nervous activities.

Track 09: Neuroendocrinology

It is the study of interactions between the nervous system and the endocrine system, also biological features of the cells involved and their communications. Most Important aspects of neuroendocrinology are insulin receptor and hypothalamic programming; stress, coping and interactions, neuro-endocrine-immune symphony, pituitary structure and hormone secretion.

Track 10: Alzheimer's Disease and Dementia

Alzheimer's is a type of dementia that causes problems with memory, thinking and behaviour. Symptoms usually develop slowly and become severe enough to interfere with daily tasks. Amyloid plaques are also found in the brain of Alzheimer patients. Neurocognitive effects associated with therapeutic drugs and animal cognition and behaviour - Fear and aversive learning and memory.

Track 11: Parkinson disease

It is a progressive and chronic disorder, caused by death or malfunctioning of neurons, genetic mutation leading to decreased level of dopamine secretion. Associated effects are anxiety; depression, stress, ageing and neurodegenerative disorders, disease diagnostics, drug designing and therapeutics are the research areas.

Track 12: Molecular Neuropharmacology

Molecular neuropharmacology involves the study of neurons and agonist, Competitive antagonist and Non-competitive antagonist, receptors on neurons for developing new drugs that will treat neurological disorders of neurodegenerative diseases. Neurogenesis and repair refers to the growth and development of neuron. Neurons never function in isolation; they are organized into ensembles or circuits that process kinds of information which are referred as neuronal circuits. The GABA inhibitory neurotransmitter and serotonin neurotransmitter present in the central nervous system of mature vertebrate interacts with GABA receptor and 5HT receptor respectively. GABAA receptors are modulated by the channel of 5HT receptors through activation of various proteins. There are about 14 5HT receptor subtypes identified from last 20 years which are now researched for their significance in various disorders and treatments. Synaptopathy is a progressively popular term used to define main features of psychiatric and neurodegenerative diseases. It infers that brain diseases are resulted from disruption of synaptic structure and function.

Track 13: Future Aspects of Neuropharmacology

Neuropharmacology is an emerging field of science, rising exponentially with the understanding of nervous system and its related disorders, drugs and treatments. The major area of research includes mechanisms of novel drugs, neuro stem cell therapy, immunoglobulin therapy, gene therapy in neuronal disorders and neural engineering.

Special Issues

 All accepted abstracts will be published in respective Conference Series LLC Journals.

• Neurochemistry & Neuropharmacology: Open Access
• Journal of Neurological Disorders
• Journal of Neurology & Neurophysiology

 Abstracts will be provided with Digital Object Identifier by Cross Ref.

See more at: http://neuro.pharmaceuticalconferences.com